KEYNOTE-905 (EV-303): NCT03924895: Phase 3: Periop Pembro + Cystectomy or Periop Pembro + Enfortumab Vedotin + Cystectomy Versus Cystectomy Alone in (Cis ineligible) Muscle-invasive Bladder Cancer
First Posted 2019-04-23 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). 2023 ASCO Genitourinary Cancers Symposium Click here for details Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin
Dec 18, 2025
KEYNOTE-A18: NCT04221945: Phase 3: Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer
First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic
Dec 15, 2024
KEYNOTE-A39 : NCT04223856: Phase 3: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
First Posted 2020-01-10 Trial status Active, not recruiting Sponsor Astellas Pharma Global Development, Inc. Abstract Presentation Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer ESMO - 11 Mar 2024 Click here for details Peer-reviewed journal publication Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 6, 2024 - N Engl J
Dec 15, 2023
KEYNOTE-522: NCT03036488: Phase 3: Study of Pembrolizumab (MK-3475) Plus Chemo vs Placebo Plus Chemo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy
First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm
Dec 15, 2021
KEYNOTE - 826: NCT03635567: Phase 3: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy First line Cervical cancer
First Posted 2018-08-17 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. June 3, 2023 2023 ASCO Annual Meeting Click here for details Peer-reviewed journal publication Pembrolizumab for Persistent, Recurrent, or Metastati
Dec 15, 2021